摘要
目的:探讨血清甲状腺球蛋白抗体(TGAb)和甲状腺微粒体抗体(TMAb)水平对Graves病(GD)甲状腺功能亢进症(甲亢)患者131I治疗后甲减发生的影响。方法收集自2009.1~2013.2在我院就诊并行131I治疗的甲亢患者142例,按血清TGAb和TMAb水平将所有患者分为四组:G1组:TGAb、TMAb均阴性;G2组:TGAb、TMAb均阳性;G3组:TGAb阳性、TMAb阴性;G4组:TGAb阴性、TMAb阳性,分析血清TGAb和TMAb水平对甲减发生的影响。结果患者总甲减发生率为31.0%,131I治疗后甲减发生率各组间比较,G2、G4组与G1组相比较差异有统计学意义(P<0.05)。结论 TGAb与TMAb是131I治疗Graves致早发甲减的一个重要影响因素,治疗前TGAb、TMAb检测对预测甲减发生率有参考价值。
Objective To investigate ef ects of thyroglobulin antibody(TGAb)and thyroid microsomal antibody(TMAb)in inducing premature hypothyroidism of patients with Graves after 131I therapy.Methods 142 cases with hyperthyroidism col ected in our hospital from january 2009 to february 2013 and treated with 131I,according to levels of TGAb and TMAb in al patients,were divided into four groups:group G1,TGAb and TMAb were negative;group G2,TGAb andTMAb were positive;group G3,TGAb was positive and TMAb was negative;group G4,TGAb was negative and TMAb was posive.To analyse ef ects of TGAb and TMAb on the incidence of early hypothyroidism.Results The total incidence rate of hypothyroidism was 31.0%,it had significant dif erence between group G2,G4 and G1 treated with 131I(P<0.05).Conclusion TGAb and TMAb are major factors of the incidence of premature hypothyroidism of patients with Graves after 131I therapy.They have reference value in forecasting incidence of hypothyroidism before treatment.
作者
王小丽
刘瑞东
WANG Xiao-li;LIU Rui-dong(Taishan Medical College Affiliated Laiwu Municipal People's Hospital,Department of Clinical Laboratory,Laiwu Shandong 271100,China)
